Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Wnt Pathway Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LRP6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRP6 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View LRP6 Products |
| Gene Delivery | LRP6 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and functional Wnt signaling assays. |
View LRP6 Products |
| Benchmark Ab | Anti-LRP6 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View LRP6 Products |
| Validator | LRP6 siRNA Set For knockdown verification and target specificity validation. |
View LRP6 Products |
| Related Target A | LRP5 High-homology co-receptor (71% identity); critical for off-target screening and selectivity profiling. |
View LRP5 Products |
| Related Target B | DKK1 Endogenous LRP6 antagonist; essential for competitive binding and ligand-blocking assays. |
View DKK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Domain-specific blocking (E1-E2 vs E3-E4) | Recombinant LRP6 truncations and domain-specific fragments strictly verified by mass spectrometry |
| LRP5/LRP6 homology cross-reactivity | High-purity LRP5 and LRP6 ortholog proteins available with >95% purity for comparative SPR/ELISA |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and recombinant DKK1/Wnt ligands included |
| False Positives in Cell Assays | Validated siRNA sets and Lentiviral ORF constructs included for functional specificity checks |
Live LRP6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LRP6 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific antibodies and Antibody-Drug Conjugates (ADCs). As first-generation broad Wnt inhibitors faced toxicity challenges, the next wave of R&D is targeting tumor-specific LRP6 conformations, domain-selective blocking (selectively targeting E1-E2 or E3-E4 to block specific Wnt ligands), and leveraging LRP6 internalization for targeted payload delivery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Biotech Innovators | Solid Tumors (TNBC, CRC, HCC) | Internalization Assay (Need high-purity, natively glycosylated LRP6 ECD-Fc) |
| Bispecific / Multi-specific | Pharma Leads | Wnt-driven Cancers, Osteoporosis | Selectivity Screening (Need LRP5 vs LRP6 comparative proteins) |
| Small Molecule / Peptide | Academic & Biotech | Metastatic Cancers, Fibrosis | Competitive Binding Assay (Need bioactive-grade DKK1 and Wnt3a ligands) |